Wegovy® tablets and heartburn

Burning chest or sore stomach? Two different entries

Trial records rarely say “heartburn”. They code what people describe under medical terms, and two of them matter here. Gastroesophageal reflux disease (GERD) means stomach contents rising into the food pipe; NIH describes the typical feeling as a painful burn in the middle of the chest, behind the breastbone, sometimes with a taste of food or acid in the mouth ^[5]. Dyspepsia, or indigestion, sits lower: pain, burning or discomfort in the upper belly, feeling full too early in a meal or uncomfortably full after a small one, sometimes with bloating, nausea or belching ^[6].

NIH states that the two are separate conditions that can occur together ^[6], and MedlinePlus notes that heartburn is sometimes confused with dyspepsia ^[7]. The distinction matters here because the tablet figures for the two differ, and because the Wegovy® Medication Guide lists both “heartburn” and “upset stomach” among the most common side effects ^[1]. A third neighbouring term, gastritis (an inflamed stomach lining), appears in the EU leaflet with stomach ache, nausea or vomiting as its signs ^[2].

What the 25 mg tablet trial recorded

Two documents carry tablet-specific numbers. The EU summary of product characteristics (SmPC) reports selected digestive reactions from OASIS 4 over its 64 treatment weeks ^[2]. The ClinicalTrials.gov record for the same study (NCT05564117), where the sponsor entered results in February 2026, lists every treatment-emergent event that reached 5% in either group between week 0 and week 71, whatever its cause; it is an official registry entry, not a peer-reviewed paper ^[3]. The published trial report confirms the overall picture: digestive adverse events were reported by 74.0% on the tablet and 42.2% on placebo ^[4].

Reading those rows

Indigestion was roughly twice as frequent on the tablet as on placebo; reflux disease was less common and the gap was smaller. Because the registry shows only events that crossed the 5% line, the gastritis row means “below 5% in both groups”, not “never seen”. Keep the trial’s size in mind too: in a tablet group of 204, each person who reported a symptom moves the figure by about half a percentage point.

The US prescribing information covers both the weekly injection and the daily tablet. For the tablet it describes Study 7, the same trial as OASIS 4: 204 adults without type 2 diabetes who took 25 mg for up to 64 weeks, followed by seven weeks off treatment. Rather than printing its own table, the label says the kinds and rates of common reactions in that study resembled those in Table 3, the injection table ^[1].

Table 3 itself is injection data from three 68-week studies of 2.4 mg weekly: dyspepsia 9% versus 3% on placebo, GERD 5% versus 3%, and gastritis 4% versus 1%, where gastritis also counts chronic, erosive and reflux gastritis ^[1]. Those rates should not be quoted as tablet figures. For the tablet itself, the label reports that severe digestive reactions affected 2% versus 0% on placebo, and that 3.4% versus 2% stopped treatment because of a digestive reaction ^[1]. Canada’s Wegovy® monograph covers only the injection, so it adds nothing for the pill ^[14].

When it tends to appear and how long it lasts

The EU table marks indigestion, reflux and gastritis as reactions seen mainly while the dose is being stepped up, and its OASIS 4 description calls most digestive events, indigestion among them, mild to moderate and brief ^[2]. The EU tablet leaflet adds that upset stomach and indigestion usually go away over time ^[2]. In the US, the tablet schedule in section 2.3 rises from 1.5 mg through 4 mg and 9 mg to 25 mg, a climb the label sets out to lower the risk of digestive reactions; if a step is not tolerated, it allows the prescriber to delay the next one ^[1].

Neither document gives a typical duration for heartburn, and the trial reports do not say whether reflux returned once the maintenance dose was reached. If it keeps coming back or bothers you, report it ^[1].

What could be behind it

• Supported by the label: semaglutide slows the emptying of the stomach (US section 12.2), the Medication Guide repeats this, and digestive reactions cluster around dose increases ^[1].
• Seen in pooled research, not specific to the pill: a 2025 meta-analysis of 55 placebo-controlled trials with 106,395 participants found that GLP-1 medicines probably raise the risk of reflux disease (risk ratio 2.19, about 4 extra cases per 1,000 people), with a stronger signal in weight-management trials and at higher doses, although those subgroup differences were not statistically significant ^[10].
• Plausible but not shown: a scintigraphy study of a 10 mg tablet in 26 healthy men found that the tablet breaks down completely in the stomach ^[11], and the manufacturer explains that its absorption enhancer, SNAC, helps semaglutide cross the stomach lining ^[12]. No source here links either fact to heartburn, and the EU text calls the tablet’s safety profile consistent with the injection’s ^[2].
• General background: NIH lists obesity, pregnancy, smoking and a hiatal hernia among the things that weaken the valve at the lower end of the food pipe and lead to reflux ^[5].

Heartburn that may not be the tablet

Many everyday medicines can cause or worsen these symptoms. For reflux, NIH and MedlinePlus name, among others, anti-inflammatory painkillers (NSAIDs), some blood pressure drugs (calcium channel blockers), sedatives, tricyclic antidepressants, some asthma medicines and progestin ^[5][7]. For indigestion, NIH adds certain antibiotics, iron supplements, steroids and medicines for osteoporosis, as well as stomach ulcers and infections such as Helicobacter pylori ^[6]. MedlinePlus warns against changing or stopping any medicine on your own ^[7].

Timing can help sort things out. A burn that arrives after a large, fatty or spicy meal, or when you lie down, fits a reflux pattern ^[7][9]; pain that sits in the upper belly with early fullness fits indigestion ^[6].

Acid remedies and the morning routine

Three findings in the product information bear on acid medicines. Omeprazole, a proton pump inhibitor, did not change semaglutide levels from the tablet in a clinically relevant way ^[1][2]. People with chronic gastritis or reflux disease absorbed the tablet much like others, a result the EU document bases on studies in people with type 2 diabetes ^[1][2]. And when the tablet was swallowed together with five other tablets, semaglutide exposure fell by 34%, which the EU text reads as other tablets in the stomach interfering with absorption ^[2]. These are interaction findings, not treatment advice.

The practical consequence is the label’s timing rule. The tablet is taken in the morning on an empty stomach with water only, no more than 4 ounces (about 120 mL), and nothing else goes in for at least 30 minutes: no food, no other drinks, no other oral medicines ^[1]. A chewable antacid counts as an oral medicine. NIH notes that antacids, H2 blockers and proton pump inhibitors are sold without a prescription, and that antacids are meant for mild symptoms rather than daily use unless a doctor agrees ^[8]. Which product to use and how to time it around the tablet is a question for your pharmacist, and the Medication Guide asks you to tell your provider about every over-the-counter medicine you take ^[1].

Everyday habits NIH and MedlinePlus describe

Public health pages list similar steps for reflux: smaller meals; not lying down, bending over or exercising soon after eating; leaving a gap between the last meal and bedtime; raising the head end of the bed; loose clothing around the waist; and not smoking ^[7][8][9]. They also name foods and drinks that commonly set it off, such as high-fat or spicy dishes, chocolate, mint, citrus, tomatoes, alcohol, caffeine and fizzy drinks ^[7][9]. The manufacturer’s patient page suggests asking your provider whether to avoid fatty, greasy or spicy food and lying down after meals ^[13].

One detail belongs to the tablet: the first coffee of the day waits until the 30 minutes are over ^[12]. If a procedure under general anaesthesia or deep sedation is coming up, tell the team that you take Wegovy®, because it slows stomach emptying and the label describes rare reports of stomach contents entering the lungs ^[1].

Wegovy® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.

When to get help